Skip to main content
. 2017 Oct 27;8(57):97490–97503. doi: 10.18632/oncotarget.22142

Figure 4. Treatments combining inhibition of HSP90 with hyperthermia (HT) and IR/cisplatin affect the cell cycle progression and cell fate.

Figure 4

(A-D) Cells were preincubated with vehicle or 30 nM Ganetespib (HSP90-i) for 30 min at 37°C, then mock-treated or exposed to 2 Gy of γ-radiation and incubated at 37 (control) or 42°C (HT) for one hour. Medium was then refreshed and cells were imaged for 96 h at intervals of 15 min. (E-H) Cells were preincubated with vehicle or 30 nM HSP90-i and/or 3.3 μM cisplatin (Cispl.) for 30 min at 37°C and then incubated at 37 (control) or 42°C (HT) for 60 min. Medium was refreshed and cells were imaged for 96 h at time intervals of 15 min. (A, E) Representative pictures of SiHa and HeLa cells at 48 h after the indicated treatments. (B, F) Average percentage of cells that successfully divided within a single (23h for SiHa and 24h for HeLa) or double (48 h) cell cycle time (+ two standard deviations). (C, G) Cell cycle times measured as the time between the first and second mitosis after the indicated treatments. (D, H) Fate of the daughter cells directly after the second mitosis. The numbers of cells analyzed in each individual treatment/measurement group are shown in Supplementary Figure 2.